JP2019521958A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521958A5 JP2019521958A5 JP2018558278A JP2018558278A JP2019521958A5 JP 2019521958 A5 JP2019521958 A5 JP 2019521958A5 JP 2018558278 A JP2018558278 A JP 2018558278A JP 2018558278 A JP2018558278 A JP 2018558278A JP 2019521958 A5 JP2019521958 A5 JP 2019521958A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- pharmaceutical composition
- formula
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- -1 amino, hydroxy, mercapto Chemical class 0.000 claims 5
- 125000005257 alkyl acyl group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 125000000262 haloalkenyl group Chemical group 0.000 claims 2
- 125000000232 haloalkynyl group Chemical group 0.000 claims 2
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical group C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 0 CC(C1)(C2)C(C3)(C4)C1CC3(C)CC24NC(OCOC(*)=O)=O Chemical compound CC(C1)(C2)C(C3)(C4)C1CC3(C)CC24NC(OCOC(*)=O)=O 0.000 description 4
- OYPFWMGNTJYQJZ-UHFFFAOYSA-N CC(C)C(OCOC(NC1(CC(C2)C3)CC3(C)CC2(C)C1)=O)=O Chemical compound CC(C)C(OCOC(NC1(CC(C2)C3)CC3(C)CC2(C)C1)=O)=O OYPFWMGNTJYQJZ-UHFFFAOYSA-N 0.000 description 1
- VCQBFNSXOLPCAT-UHFFFAOYSA-N CC(CC(C1)C2)(CC1(C)C1)CC21NC(OCCl)=O Chemical compound CC(CC(C1)C2)(CC1(C)C1)CC21NC(OCCl)=O VCQBFNSXOLPCAT-UHFFFAOYSA-N 0.000 description 1
- FXSNLUFXBYVKLU-UHFFFAOYSA-N CC(CC(C1)C2)(CC1(C)C1)CC21NC(OCOC(C)=O)=O Chemical compound CC(CC(C1)C2)(CC1(C)C1)CC21NC(OCOC(C)=O)=O FXSNLUFXBYVKLU-UHFFFAOYSA-N 0.000 description 1
- MVDDHUPQCZMTCM-UHFFFAOYSA-N CC(CC(C1)C2)(CC1(C)C1)CC21NC(OCOC(Cc1c(cccc2)c2ccc1)=O)=O Chemical compound CC(CC(C1)C2)(CC1(C)C1)CC21NC(OCOC(Cc1c(cccc2)c2ccc1)=O)=O MVDDHUPQCZMTCM-UHFFFAOYSA-N 0.000 description 1
- NQXPVFOCJHDBIU-UHFFFAOYSA-N CCCCCCCC(OCOC(NC1(CCC)CC(C)(CCC2)CC2C1)=O)=O Chemical compound CCCCCCCC(OCOC(NC1(CCC)CC(C)(CCC2)CC2C1)=O)=O NQXPVFOCJHDBIU-UHFFFAOYSA-N 0.000 description 1
- JVLLYAOFSSMIEK-UHFFFAOYSA-N CCCCCCCCCCCCCC(OCOC(NC1(CC(C2)C3)CC3(C)CC2(C)C1)=O)=O Chemical compound CCCCCCCCCCCCCC(OCOC(NC1(CC(C2)C3)CC3(C)CC2(C)C1)=O)=O JVLLYAOFSSMIEK-UHFFFAOYSA-N 0.000 description 1
- XULMRGWLPIEGJB-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(OCOC(NC1(CC(C2)C3)CC3(C)CC2(C)C1)=O)=O Chemical compound CCCCCCCCCCCCCCCC(OCOC(NC1(CC(C2)C3)CC3(C)CC2(C)C1)=O)=O XULMRGWLPIEGJB-UHFFFAOYSA-N 0.000 description 1
- DTDIVFCRUVBYLK-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCC(OCOC(NC1(CC(C2)C3)CC3(C)CC2(C)C1)=O)=O Chemical compound CCCCCCCCCCCCCCCCCC(OCOC(NC1(CC(C2)C3)CC3(C)CC2(C)C1)=O)=O DTDIVFCRUVBYLK-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021074004A JP2021119163A (ja) | 2016-05-07 | 2021-04-26 | メマンチン化合物及びその調整並びにその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610300245 | 2016-05-07 | ||
| CN201610300245.5 | 2016-05-07 | ||
| PCT/CN2017/083129 WO2017193870A1 (en) | 2016-05-07 | 2017-05-05 | Memantine compounds and their preparation and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074004A Division JP2021119163A (ja) | 2016-05-07 | 2021-04-26 | メマンチン化合物及びその調整並びにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521958A JP2019521958A (ja) | 2019-08-08 |
| JP2019521958A5 true JP2019521958A5 (enExample) | 2020-05-07 |
| JP6884800B2 JP6884800B2 (ja) | 2021-06-09 |
Family
ID=60266756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558278A Active JP6884800B2 (ja) | 2016-05-07 | 2017-05-05 | メマンチン化合物及びその調整並びにその使用 |
| JP2021074004A Pending JP2021119163A (ja) | 2016-05-07 | 2021-04-26 | メマンチン化合物及びその調整並びにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074004A Pending JP2021119163A (ja) | 2016-05-07 | 2021-04-26 | メマンチン化合物及びその調整並びにその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US10800734B2 (enExample) |
| JP (2) | JP6884800B2 (enExample) |
| CN (2) | CN109152752A (enExample) |
| WO (1) | WO2017193870A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10800734B2 (en) * | 2016-05-07 | 2020-10-13 | Sunshine Lake Pharma Co., Ltd. | Memantine compounds and their preparation and uses thereof |
| CN109959731B (zh) * | 2017-12-26 | 2022-07-08 | 广东东阳光药业有限公司 | 一种用hplc法测定美金刚衍生物的方法 |
| CN110433131B (zh) * | 2018-05-03 | 2024-09-03 | 广东东阳光药业股份有限公司 | 一种药物组合物 |
| CN111662216A (zh) * | 2019-03-05 | 2020-09-15 | 广东东阳光药业有限公司 | 一种金刚烷胺类化合物的晶型及其制备方法 |
| JP2022553229A (ja) * | 2019-10-16 | 2022-12-22 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 薬物組成物 |
| WO2024012565A1 (zh) * | 2022-07-15 | 2024-01-18 | 广州市恒诺康医药科技有限公司 | 美金刚衍生物、其药物组合物及其用途 |
| WO2025011640A1 (zh) * | 2023-07-13 | 2025-01-16 | 广州市恒诺康医药科技有限公司 | 美金刚衍生物、其药物组合物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614560A (en) * | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US6444702B1 (en) * | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
| CN100351225C (zh) | 2004-10-28 | 2007-11-28 | 中国医学科学院医药生物技术研究所 | 一组金刚烷胺类衍生物及其合成方法和作为神经元损伤保护剂的应用 |
| JP2010026942A (ja) * | 2008-07-23 | 2010-02-04 | Hitachi Ltd | 情報処理システム |
| WO2013088255A1 (en) * | 2011-12-15 | 2013-06-20 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
| EP2961403A4 (en) | 2013-03-01 | 2016-11-30 | Zalicus Pharmaceuticals Ltd | HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL |
| CN103553932B (zh) | 2013-11-12 | 2015-03-25 | 江苏正大清江制药有限公司 | 一种适合工业化制备盐酸美金刚的方法 |
| CN108024990B (zh) | 2015-08-31 | 2020-08-11 | 深圳青雅启瑞生物科技有限公司 | 美金刚与牛蒡子苷元的缀合物及其组合物和用途 |
| US10800734B2 (en) * | 2016-05-07 | 2020-10-13 | Sunshine Lake Pharma Co., Ltd. | Memantine compounds and their preparation and uses thereof |
-
2017
- 2017-05-05 US US16/094,848 patent/US10800734B2/en active Active
- 2017-05-05 JP JP2018558278A patent/JP6884800B2/ja active Active
- 2017-05-05 CN CN201780027329.9A patent/CN109152752A/zh active Pending
- 2017-05-05 WO PCT/CN2017/083129 patent/WO2017193870A1/en not_active Ceased
- 2017-05-05 CN CN202110652331.3A patent/CN113336673A/zh active Pending
-
2020
- 2020-09-08 US US17/014,746 patent/US20200399208A1/en not_active Abandoned
-
2021
- 2021-04-26 JP JP2021074004A patent/JP2021119163A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521958A5 (enExample) | ||
| JP2015514135A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| MX2020000268A (es) | Agonista de fxr. | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| MX2010007375A (es) | Nuevos derivados de lupano. | |
| JP2015531773A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| WO2019035914A8 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| JP2017533968A5 (enExample) | ||
| JP2019532067A5 (enExample) | ||
| JP2019522055A5 (enExample) | ||
| PH12022550876A1 (en) | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases | |
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| JP2015522551A5 (enExample) | ||
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2018502101A5 (enExample) | ||
| WO2010005580A3 (en) | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
| JP2019535723A5 (enExample) | ||
| JP2017522304A5 (enExample) | ||
| RU2013136895A (ru) | Новое бициклическое соединение или его соль |